Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00087633 · ClinicalTrials.gov registry record · Phase 4

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

A Phase 4 study of Hepatitis C, Chronic, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 4
Development phase
115
Enrollment target
20
Study locations

NCT00087633 is a Phase 4 study of Hepatitis C, Chronic that has completed, run by Hoffmann-La Roche. The registered enrollment target is 115 participants, below the 372-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00087633, a Phase 4 study of Hepatitis C, Chronic, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 4
Development phase
115 participants
Enrollment target
20
Study locations

Study Summary

This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection. The anticipated time on study treatment was 3-12 months, and the target sample size was 100-500 individuals.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG Copegus
  • DRUG peginterferon alfa-2a [Pegasys]

Study Locations (20)

California

  • - Los Angeles
  • - San Francisco
  • - San Francisco

Florida

  • - Gainesville
  • - Jacksonville
  • - Miami

Minnesota

  • - Minneapolis
  • - Rochester

New York

  • - New York
  • - New York

Alabama

  • - Birmingham

Arizona

  • - Phoenix

Colorado

  • - Aurora

Illinois

  • - Chicago

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2004-10
Est. Completion 2008-10
Phase Phase 4

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00087633

The ClinicalTrials.gov registry entry for NCT00087633 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (69% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Copegus is the first listed.

NCT00087633 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00087633 about?

NCT00087633 is a clinical study titled "PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.". This 2-arm study was designed to evaluate the efficacy, safety, and tolerability of prophylactic PEGASYS plus COPEGUS after liver transplantation for hepatitis C, compared to initiation of antiviral therapy at the time of clinical recurrence of hepatitis C infection. The anticipated time on study tr...

What is the current status of trial NCT00087633?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 115 participants. The study started on 2004-10. Estimated completion is 2008-10.

What conditions does trial NCT00087633 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT00087633?

The interventions under investigation include: Copegus (DRUG), peginterferon alfa-2a [Pegasys] (DRUG).

Who is sponsoring clinical trial NCT00087633?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00087633 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C, Chronic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.